EA
TVTX icon

Emerald Advisers’s Travere Therapeutics TVTX Stock Holding History

Emerald Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.9M Buy
1,600,886
+43,690
+3% +$1.94M 2.14% 1
2026
Q1 		$46.3M Sell
1,557,196
-36,988
-2% -$1.11M 1.46% 12
2025
Q4 		$60.9M Sell
1,594,184
-552,583
-26% -$18M 1.88% 5
2025
Q3 		$51.3M Buy
2,146,767
+55,407
+3% +$1.04M 1.64% 11
2025
Q2 		$31M Buy
2,091,360
+14,187
+0.7% +$235K 1.13% 28
2025
Q1 		$37.2M Sell
2,077,173
-48,571
-2% -$986K 1.68% 11
2024
Q4 		$37M Buy
2,125,744
+165,085
+8% +$2.92M 1.43% 13
2024
Q3 		$27.4M Buy
1,960,659
+323,513
+20% +$3.37M 1.06% 33
2024
Q2 		$13.5M Sell
1,637,146
-112,255
-6% -$756K 0.56% 62
2024
Q1 		$13.5M Buy
1,749,401
+703,252
+67% +$5.93M 0.54% 77
2023
Q4 		$9.4M Sell
1,046,149
-14,153
-1% -$103K 0.4% 96
2023
Q3 		$9.48M Buy
1,060,302
+417,250
+65% +$5.89M 0.46% 92
2023
Q2 		$9.88M Buy
+643,052
New +$11.7M 0.43% 91

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Advisers's TVTX Position: Q2 2026 in Review

Emerald Advisers increased its Travere Therapeutics (TVTX) stake by 2.8% in Q2 2026, buying an estimated $1.94M and bringing the position to 1,600,886 shares worth $90.9M. The position accounts for 2.14% of the portfolio, ranked #1.

Emerald Advisers first reported a position in TVTX in Q2 2023 and has held it in 13 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Emerald Advisers held 1,600,886 shares of Travere Therapeutics worth $90.9M as of Q2 2026.
  • Emerald Advisers bought 43,690 Travere Therapeutics shares in Q2 2026, an estimated $1.94M.
  • Travere Therapeutics made up 2.14% of Emerald Advisers's portfolio in Q2 2026, its #1 holding.
  • Emerald Advisers first reported a position in Travere Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.